BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 7700906)

  • 1. Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide.
    Skórski T; Kawalec M; Kawiak J
    Cancer Immunol Immunother; 1990; 32(1):71-4. PubMed ID: 2289201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP; Rogers PC; Chan KW; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seraspenide (AcSDKP) mediated protection of hematopoietic stem cells in a hyperthermic purging protocol.
    Wierenga PK; Konings AW
    Prog Clin Biol Res; 1994; 389():189-95. PubMed ID: 7700902
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
    Kramer B; Makrynikola V; Bradstock K
    Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
    [No Abstract]   [Full Text] [Related]  

  • 6. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
    Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R; Bony V; Lopez M
    Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
    [No Abstract]   [Full Text] [Related]  

  • 8. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of amifostine (Ethyol) in haematological malignancies.
    Gorin NC
    Eur J Cancer; 1996; 32A Suppl 4():S31-9. PubMed ID: 8976820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of marrow purging].
    Rizzoli V; Carlo-Stella C; Mangoni L
    Haematologica; 1991 Jun; 76 Suppl 3():311-20. PubMed ID: 1684346
    [No Abstract]   [Full Text] [Related]  

  • 11. Negative selection and protection of normal progenitor cells for autografting.
    Douay L
    Bone Marrow Transplant; 1998 Sep; 22(5):423-30. PubMed ID: 9733264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is our current strategy in manipulating hemopoiesis in autologous transplantation correct?
    To LB
    Stem Cells; 1993 Jul; 11(4):283-9. PubMed ID: 8104615
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.